The complex interplay between genetics and the environment results in the wide range of pathogenesis and severity seen in children with atopic dermatitis.
- Children of parents who both have allergies have a 5-fold increased risk of early-onset atopic dermatitis.
- Twin studies reveal a concordance rate of 72% in monozygotic twins and 23% in dizygotic twins.
- The mutation of a protein found in the stratum corneum (filaggrin) is implicated in some patients with atopic dermatitis. Not all patients with a filaggrin defect develop atopic dermatitis.
The skin lesions of atopic dermatitis develop because of deformations in the skin barrier and imbalances in the adaptive immune system.
Risk Factors
Various environmental, genetic, and social factors have been investigated to determine whether they contribute to the risk of developing atopic dermatitis. Numerous studies conclude that the most important of these are a family history of atopy and loss of function mutation in the FLG gene. Both are strongly associated with atopic dermatitis.
Other factors have been studied but show either no correlation or insufficient evidence to support a contribution to the development of atopic dermatitis. These include
The complexity in the causes, symptoms, and disease course of atopic dermatitis means that primary prevention efforts are difficult to study.
The fact that not all infants with FLG gene mutations develop atopic dermatitis suggests that primary prevention may be possible.
Some studies show that emollients begun in the neonatal period may reduce the incidence of atopic dermatitis in infants who are at high risk for atopy.
- A systematic review and meta-analysis showed that emollient therapy can be used for the prevention of atopic dermatitis.
- Application of moisturizer to neonates prevents development of atopic dermatitis.
- Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention.
Determining the environmental factors that complement genetic components is a topic of current research efforts.
![]()
The development of this information was made possible with support from Sanofi and Regeneron. The AAP maintains full independence in its editorial and strategic activities. Financial supporters have no influence over AAP content, policies, or leadership decisions.
Last Updated
03/03/2026
Source
American Academy of Pediatrics